{"success":true,"data":{"pressRelease":{"id":"125139","rtpr_id":"nACSBkfvMa","ticker":"OSRH","exchange":"NASDAQ","all_tickers":["OSRH"],"title":"OSR Health: Preparing Our Appeal, Advancing Our Catalysts, Continuing Our Mission ","author":"ACCESSWIRE","published_at":"2026-08-21T15:46:19.766Z","article_body":"The Company details its Nasdaq hearing request, its $15 million Put Option,\nand continued development across its subsidiary pipeline\n\nBELLEVUE, WA / ACCESS Newswire (https://www.accessnewswire.com/) / August 21,\n2026 / OSR Health, Inc. (NASDAQ:OSRH) today released the following letter from\nits Chief Executive Officer to shareholders.\n\nTo OSR Health Shareholders:\n\nI am aware that many of you are watching closely to see what comes next. I\nwant to address some of your concerns directly and with specificity.\n\nOSR Health's stock is showing resilience this morning after a difficult\nsession yesterday. In our opinion, that resilience reflects something real:\nthe conviction of shareholders who understand this Company and its potential.\n\nWHAT IS HAPPENING AND WHAT WE ARE DOING\n\nWe received the Nasdaq Staff Delisting Determination on August 19, which we\ndisclosed immediately, as required. We are now preparing our formal request\nfor a hearing before the Nasdaq Independent Hearings Panel, which we plan to\nsubmit no later than August 26.\n\nI want to be clear about what this hearing represents. It is a formal appeal\nbefore an independent Panel, in which we will present the case for OSR\nHealth's continued listing based on documented evidence and a near-term\ncompliance plan. We are approaching this hearing with the same diligence and\npreparation with which we have addressed our challenges over the past several\nmonths.\n\nOur case to the Panel will rely on more than the extraordinary trading\nactivity of August 17 and 18, although we believe that record speaks\npowerfully for itself. Our case will also rely on the fundamental value of\nwhat this company has built and on a realistic, near-term plan to demonstrate\ncompliance.\n\nTHE PUT OPTION - A NEAR-TERM CATALYST\n\nI want to speak plainly about our Put Option, because I believe the market has\nnot fully appreciated what it represents.\n\nAs part of the VXM01 Global Exclusive License Agreement executed in April\n2026, OSR Health holds a Put Option exercisable against BCM Europe AG, a Swiss\nlife sciences investment firm backed by South Korean pharmaceutical investors,\nfor $15 million in cash proceeds upon exercise. The option is exercisable from\nOctober 29, 2026, at an exercise price of $10.00 per share.\n\nRespectfully, I ask you to consider what that means. BCM Europe agreed to\ninvest in newly issued shares of our Company at $10.00 per share - a\nsignificant premium to the current market price as the Global License\nAgreement did not include an upfront cash payment. In its place, the parties\nstructured the $15 million Put Option, exercisable at $10.00 per share, and\nagreed that this price would serve as an objective reference for the Company's\nvalue set by an institutional counterparty. It reflects a considered,\nthird-party institutional assessment of the value of VXM01 by Avance Life\nSciences AG, a premier Swiss life sciences consultancy. And yet OSR Health's\nshares trade today at a fraction of that figure.\n\nI am not in a position to predict when or how the market will close that gap.\nWhat I can confirm is this: the Put Option contractual right remains\nunchanged. It is legally defined and protected under the Global License\nAgreement. Our management and BCM Europe have been in active communication\nwith BCM Europe's end investors in Korea regarding their capacity to accept\nand settle our exercise of the option in October. While we have determined\nthat moving up the exercise date is not currently a practicable option, we\nconfirm that the $15 million Put Option exercisable from October 29, 2026\nremains unchanged and exercisable in accordance with terms from that date.\n\nFor some additional context: at today's share price, the Company's entire\nmarket capitalization is smaller than the cash proceeds we are contractually\nentitled to receive from the exercise of this single option. We believe that\ndisconnect, in time, will be corrected by the market.\n\nOUR PIPELINE CONTINUES\n\nOur listing status does not slow our business. Woori IO and Darnatein plan to\ncontinue their development activities, and we will provide business\ndevelopment updates from both subsidiaries as material developments warrant.\nOSR Health's mission - building an Innovation Headquarters for global\nhealthcare - also continues forward in spite of our current challenges.\n\nThe period ahead is not without uncertainty. The trading suspension on August\n26 will be a difficult moment for many of our shareholders, and I do not\nminimize that.\n\nWe are managing this situation proactively. We have a hearing to prepare, a\nregistration statement to file for our CVR program, a Put Option to exercise,\nand a business to continue building. The work continues every day.\n\nWe will continue to update you at every meaningful milestone.\n\nSincerely,\n\nPeter Hwang\nChief Executive Officer\nOSR Health, Inc. (NASDAQ:OSRH)\n\nAbout OSR Health, Inc.\n\nOSR Health, Inc. (NASDAQ:OSRH) is a global healthcare holding company\ndedicated to advancing biomedical innovations in health and wellness. Through\nits subsidiaries, OSR Health engages in immuno-oncology, regenerative\nbiologics, and medical device technologies to improve health outcomes\nworldwide. Learn more at www.OSR-Health.com.\n\nInvestor Contact\n\nOSR Health, Inc.\nInvestor Relations\nir@osr-health.com\n\nForward-Looking Statements\n\nThis communication contains forward-looking statements within the meaning of\nthe Private Securities Litigation Reform Act of 1995, including statements\nregarding the Company's planned Nasdaq hearing request, the BCM Europe AG Put\nOption, the CVR program and related S-1 registration, and subsidiary\ndevelopment activities. These statements involve risks and uncertainties -\nincluding the outcome of the Nasdaq Hearings Panel proceeding, BCM Europe AG's\nability to satisfy its Put Option obligations, and other risks described in\nthe Company's SEC filings - that may cause actual results to differ\nmaterially. The Company undertakes no obligation to update these statements\nexcept as required by law.\n\nSOURCE: OSR Health, Inc.\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/biotechnology/osr-health-preparing-our-appeal-advancing-our-catalysts-continuing-our-mission-1210401)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nACSBkfvMa","title":"OSR Health: Preparing Our Appeal, Advancing Our Catalysts, Continuing Our Mission ","author":"ACCESSWIRE","ticker":"OSRH","created":"2026-08-21T15:46:19.766Z","tickers":["OSRH"],"exchange":"NASDAQ","article_body":"The Company details its Nasdaq hearing request, its $15 million Put Option,\nand continued development across its subsidiary pipeline\n\nBELLEVUE, WA / ACCESS Newswire (https://www.accessnewswire.com/) / August 21,\n2026 / OSR Health, Inc. (NASDAQ:OSRH) today released the following letter from\nits Chief Executive Officer to shareholders.\n\nTo OSR Health Shareholders:\n\nI am aware that many of you are watching closely to see what comes next. I\nwant to address some of your concerns directly and with specificity.\n\nOSR Health's stock is showing resilience this morning after a difficult\nsession yesterday. In our opinion, that resilience reflects something real:\nthe conviction of shareholders who understand this Company and its potential.\n\nWHAT IS HAPPENING AND WHAT WE ARE DOING\n\nWe received the Nasdaq Staff Delisting Determination on August 19, which we\ndisclosed immediately, as required. We are now preparing our formal request\nfor a hearing before the Nasdaq Independent Hearings Panel, which we plan to\nsubmit no later than August 26.\n\nI want to be clear about what this hearing represents. It is a formal appeal\nbefore an independent Panel, in which we will present the case for OSR\nHealth's continued listing based on documented evidence and a near-term\ncompliance plan. We are approaching this hearing with the same diligence and\npreparation with which we have addressed our challenges over the past several\nmonths.\n\nOur case to the Panel will rely on more than the extraordinary trading\nactivity of August 17 and 18, although we believe that record speaks\npowerfully for itself. Our case will also rely on the fundamental value of\nwhat this company has built and on a realistic, near-term plan to demonstrate\ncompliance.\n\nTHE PUT OPTION - A NEAR-TERM CATALYST\n\nI want to speak plainly about our Put Option, because I believe the market has\nnot fully appreciated what it represents.\n\nAs part of the VXM01 Global Exclusive License Agreement executed in April\n2026, OSR Health holds a Put Option exercisable against BCM Europe AG, a Swiss\nlife sciences investment firm backed by South Korean pharmaceutical investors,\nfor $15 million in cash proceeds upon exercise. The option is exercisable from\nOctober 29, 2026, at an exercise price of $10.00 per share.\n\nRespectfully, I ask you to consider what that means. BCM Europe agreed to\ninvest in newly issued shares of our Company at $10.00 per share - a\nsignificant premium to the current market price as the Global License\nAgreement did not include an upfront cash payment. In its place, the parties\nstructured the $15 million Put Option, exercisable at $10.00 per share, and\nagreed that this price would serve as an objective reference for the Company's\nvalue set by an institutional counterparty. It reflects a considered,\nthird-party institutional assessment of the value of VXM01 by Avance Life\nSciences AG, a premier Swiss life sciences consultancy. And yet OSR Health's\nshares trade today at a fraction of that figure.\n\nI am not in a position to predict when or how the market will close that gap.\nWhat I can confirm is this: the Put Option contractual right remains\nunchanged. It is legally defined and protected under the Global License\nAgreement. Our management and BCM Europe have been in active communication\nwith BCM Europe's end investors in Korea regarding their capacity to accept\nand settle our exercise of the option in October. While we have determined\nthat moving up the exercise date is not currently a practicable option, we\nconfirm that the $15 million Put Option exercisable from October 29, 2026\nremains unchanged and exercisable in accordance with terms from that date.\n\nFor some additional context: at today's share price, the Company's entire\nmarket capitalization is smaller than the cash proceeds we are contractually\nentitled to receive from the exercise of this single option. We believe that\ndisconnect, in time, will be corrected by the market.\n\nOUR PIPELINE CONTINUES\n\nOur listing status does not slow our business. Woori IO and Darnatein plan to\ncontinue their development activities, and we will provide business\ndevelopment updates from both subsidiaries as material developments warrant.\nOSR Health's mission - building an Innovation Headquarters for global\nhealthcare - also continues forward in spite of our current challenges.\n\nThe period ahead is not without uncertainty. The trading suspension on August\n26 will be a difficult moment for many of our shareholders, and I do not\nminimize that.\n\nWe are managing this situation proactively. We have a hearing to prepare, a\nregistration statement to file for our CVR program, a Put Option to exercise,\nand a business to continue building. The work continues every day.\n\nWe will continue to update you at every meaningful milestone.\n\nSincerely,\n\nPeter Hwang\nChief Executive Officer\nOSR Health, Inc. (NASDAQ:OSRH)\n\nAbout OSR Health, Inc.\n\nOSR Health, Inc. (NASDAQ:OSRH) is a global healthcare holding company\ndedicated to advancing biomedical innovations in health and wellness. Through\nits subsidiaries, OSR Health engages in immuno-oncology, regenerative\nbiologics, and medical device technologies to improve health outcomes\nworldwide. Learn more at www.OSR-Health.com.\n\nInvestor Contact\n\nOSR Health, Inc.\nInvestor Relations\nir@osr-health.com\n\nForward-Looking Statements\n\nThis communication contains forward-looking statements within the meaning of\nthe Private Securities Litigation Reform Act of 1995, including statements\nregarding the Company's planned Nasdaq hearing request, the BCM Europe AG Put\nOption, the CVR program and related S-1 registration, and subsidiary\ndevelopment activities. These statements involve risks and uncertainties -\nincluding the outcome of the Nasdaq Hearings Panel proceeding, BCM Europe AG's\nability to satisfy its Put Option obligations, and other risks described in\nthe Company's SEC filings - that may cause actual results to differ\nmaterially. The Company undertakes no obligation to update these statements\nexcept as required by law.\n\nSOURCE: OSR Health, Inc.\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/biotechnology/osr-health-preparing-our-appeal-advancing-our-catalysts-continuing-our-mission-1210401)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved."},"type":"article","timestamp":"2026-08-21T15:46:19.825250954Z","server_sent_at_ms":1787327179825},"received_at":"2026-08-21T15:46:19.879Z","source_url":"https://www.accessnewswire.com/newsroom/en/biotechnology/osr-health-preparing-our-appeal-advancing-our-catalysts-continuing-our-mission-1210401"},"analysis":{"id":"114096","press_release_id":"125139","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":["Nasdaq Staff Delisting Determination received","Potential trading suspension on August 26","Market cap is smaller than the $15M put option proceeds"],"eventType":"regulatory","narrative":"OSR Health disclosed that it received a Nasdaq Staff Delisting Determination on August 19 and is preparing a formal request for a hearing before the Nasdaq Independent Hearings Panel to appeal the decision.\n\nThe company highlighted a contractual Put Option with BCM Europe AG exercisable from October 29 for $15 million at $10.00 per share, arguing this institutional valuation exceeds its current market capitalization.\n\nDespite the regulatory challenges, the company stated that its subsidiaries Woori IO and Darnatein will continue their development activities.","sentiment":"bearish","agentHooks":{"shouldPost":true,"suggestedAngle":"OSR Health fights Nasdaq delisting while touting $15M put option as hidden value catalyst."},"keyFigures":{"customDimensions":{"put_option_proceeds":"$15 million","hearing_request_deadline":"August 26","put_option_exercise_date":"October 29, 2026","put_option_exercise_price":"$10.00"}},"quotedText":"At today's share price, the Company's entire market capitalization is smaller than the cash proceeds we are contractually entitled to receive from the exercise of this single option.","namedEntities":{"people":[{"name":"Peter Hwang","role":"Chief Executive Officer"}],"products":["VXM01"],"companies":[{"name":"OSR Health, Inc.","ticker":"OSRH"},{"name":"BCM Europe AG","relationship":"partner / counterparty"},{"name":"Woori IO","relationship":"subsidiary"},{"name":"Darnatein","relationship":"subsidiary"},{"name":"Avance Life Sciences AG","relationship":"consultant"}],"dollarAmounts":[{"amount":"$15 million","context":"Put Option cash proceeds"},{"amount":"$10.00","context":"Put Option exercise price per share"}]},"materialImpact":{"score":4,"reasoning":"The company received a Nasdaq Staff Delisting Determination, threatening its public listing status, though it is appealing the decision. The immediate risk of a trading suspension and potential delisting outweighs the cited value of the put option."},"tickerRelevance":{"others":[],"primary":"OSRH"},"globalImportance":25,"audienceRelevance":15,"eventTypeSecondary":["operations_update"],"importanceComponents":{"tickerTier":"micro-cap","eventGravity":"delisting_threat","sectorWeight":"biotech"}},"event_type":"regulatory","event_type_secondary":["operations_update"],"sentiment":"bearish","material_impact_score":4,"narrative":"OSR Health disclosed that it received a Nasdaq Staff Delisting Determination on August 19 and is preparing a formal request for a hearing before the Nasdaq Independent Hearings Panel to appeal the decision.\n\nThe company highlighted a contractual Put Option with BCM Europe AG exercisable from October 29 for $15 million at $10.00 per share, arguing this institutional valuation exceeds its current market capitalization.\n\nDespite the regulatory challenges, the company stated that its subsidiaries Woori IO and Darnatein will continue their development activities.","key_figures":{"customDimensions":{"put_option_proceeds":"$15 million","hearing_request_deadline":"August 26","put_option_exercise_date":"October 29, 2026","put_option_exercise_price":"$10.00"}},"named_entities":{"people":[{"name":"Peter Hwang","role":"Chief Executive Officer"}],"products":["VXM01"],"companies":[{"name":"OSR Health, Inc.","ticker":"OSRH"},{"name":"BCM Europe AG","relationship":"partner / counterparty"},{"name":"Woori IO","relationship":"subsidiary"},{"name":"Darnatein","relationship":"subsidiary"},{"name":"Avance Life Sciences AG","relationship":"consultant"}],"dollarAmounts":[{"amount":"$15 million","context":"Put Option cash proceeds"},{"amount":"$10.00","context":"Put Option exercise price per share"}]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-08-21T15:47:57.684Z","global_importance":25,"audience_relevance":15,"importance_components":{"tickerTier":"micro-cap","eventGravity":"delisting_threat","sectorWeight":"biotech"}},"durationMs":97793,"modelName":"glm-4.7"}}